Loading…
Lobbying Spend
—
Filings
58
Firms Hired
3
Active Period
2015–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
American Made Pharmaceuticals Act of 2023
2023 · fourth_quarter · Firm: RED+BLUE STRATEGIES
S. 3311 - American Made Pharmaceuticals Act of 2023 - Support for policies that encourage keeping the different elements of the prescription drug supply chain in the country to support better access to lifesaving medications and expand the number of quality jobs in the United States. Issues related to drug shortages in the United States and the role biosimilars can play. Issues related to cancer care and developing both biosimilar and novel treatments to fight disease. Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs. Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products.
Client expense: — · Firm income: $50,000
Matched citations: S. 3311
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: RED+BLUE STRATEGIES
H.R. 2617 - The Consolidated Appropriations Act for FY 2023 - Support for policy and guidance related to the treatment of American made biosimilar and generic medications as part of Buy American policies. PL 117-169 - The Inflation Reduction Act of 2022 - Support for policies focused on advancing the use of biosimilars in the Medicare program. S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2617
Advancing Education on Biosimilars Act of 2021
2022 · fourth_quarter · Firm: RED+BLUE STRATEGIES
H.R. 2617 - The Consolidated Appropriations Act for FY 2023 - Support for policy and guidance related to the treatment of American made biosimilar and generic medications as part of Buy American policies. PL 117-169 - The Inflation Reduction Act of 2022 - Support for policies focused on advancing the use of biosimilars in the Medicare program. S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $50,000
Matched citations: S. 164
American Made Pharmaceuticals Act of 2022
2022 · fourth_quarter · Firm: RED+BLUE STRATEGIES
H.R. 2617 - The Consolidated Appropriations Act for FY 2023 - Support for policy and guidance related to the treatment of American made biosimilar and generic medications as part of Buy American policies. PL 117-169 - The Inflation Reduction Act of 2022 - Support for policies focused on advancing the use of biosimilars in the Medicare program. S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $50,000
Matched citations: S. 3991
Advancing Education on Biosimilars Act of 2021
2022 · third_quarter · Firm: RED+BLUE STRATEGIES
PL 117-169 - The Inflation Reduction Act of 2022 - Support for policies focused on advancing the use of biosimilars in the Medicare program. S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $50,000
Matched citations: S. 164
American Made Pharmaceuticals Act of 2022
2022 · third_quarter · Firm: RED+BLUE STRATEGIES
PL 117-169 - The Inflation Reduction Act of 2022 - Support for policies focused on advancing the use of biosimilars in the Medicare program. S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $50,000
Matched citations: S. 3991
Advancing Education on Biosimilars Act of 2021
2022 · second_quarter · Firm: RED+BLUE STRATEGIES
S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $60,000
Matched citations: S. 164
American Made Pharmaceuticals Act of 2022
2022 · second_quarter · Firm: RED+BLUE STRATEGIES
S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $60,000
Matched citations: S. 3991
Inflation Reduction Act of 2022
2022 · first_quarter · Firm: RED+BLUE STRATEGIES
S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. H.R. 5376 - Build Back Better Act - Continued advocacy for issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5376
Advancing Education on Biosimilars Act of 2021
2022 · first_quarter · Firm: RED+BLUE STRATEGIES
S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. H.R. 5376 - Build Back Better Act - Continued advocacy for issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $60,000
Matched citations: S. 164
American Made Pharmaceuticals Act of 2022
2022 · first_quarter · Firm: RED+BLUE STRATEGIES
S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. H.R. 5376 - Build Back Better Act - Continued advocacy for issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $60,000
Matched citations: S. 3991
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: RED+BLUE STRATEGIES
H.R. 5376 - Build Back Better Act - Issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications Work to advance policies that support companies that fully manufacture products in the USA. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5376
Advancing Education on Biosimilars Act of 2021
2021 · fourth_quarter · Firm: RED+BLUE STRATEGIES
H.R. 5376 - Build Back Better Act - Issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications Work to advance policies that support companies that fully manufacture products in the USA. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $60,000
Matched citations: S. 164
Advancing Education on Biosimilars Act of 2021
2021 · third_quarter · Firm: RED+BLUE STRATEGIES
Build Back Better Act - Issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications Work to advance policies that support companies that fully manufacture products in America. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $60,000
Matched citations: S. 164
Advancing Education on Biosimilars Act of 2021
2021 · second_quarter · Firm: RED+BLUE STRATEGIES
S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $60,000
Matched citations: S. 164
Advancing Education on Biosimilars Act of 2021
2021 · first_quarter · Firm: RED+BLUE STRATEGIES
S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.
Client expense: — · Firm income: $60,000
Matched citations: S. 164
Consolidated Appropriations Act, 2021
2020 · fourth_quarter · Firm: RED+BLUE STRATEGIES
Most Favored Nation Prescription Drug Regulations and Executive Orders promulgated by the Administration and its impact on biosimilars. P.L. 116-260/H.R. 133 - Consolidated Appropriations Act of 2021 - Issues related to the fight against COVID-19 and coverage of medications indirectly related to the treatment of cancer patients during the pandemic as well as provisions designed to bolster the nation's biosimilars marketplace. H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders. Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards and coverage in the 340b program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 133
Further Consolidated Appropriations Act, 2020
2020 · fourth_quarter · Firm: RED+BLUE STRATEGIES
Most Favored Nation Prescription Drug Regulations and Executive Orders promulgated by the Administration and its impact on biosimilars. P.L. 116-260/H.R. 133 - Consolidated Appropriations Act of 2021 - Issues related to the fight against COVID-19 and coverage of medications indirectly related to the treatment of cancer patients during the pandemic as well as provisions designed to bolster the nation's biosimilars marketplace. H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders. Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards and coverage in the 340b program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1865
Elijah E. Cummings Lower Drug Costs Now Act
2020 · fourth_quarter · Firm: RED+BLUE STRATEGIES
Most Favored Nation Prescription Drug Regulations and Executive Orders promulgated by the Administration and its impact on biosimilars. P.L. 116-260/H.R. 133 - Consolidated Appropriations Act of 2021 - Issues related to the fight against COVID-19 and coverage of medications indirectly related to the treatment of cancer patients during the pandemic as well as provisions designed to bolster the nation's biosimilars marketplace. H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders. Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards and coverage in the 340b program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
2020 · fourth_quarter · Firm: RED+BLUE STRATEGIES
Most Favored Nation Prescription Drug Regulations and Executive Orders promulgated by the Administration and its impact on biosimilars. P.L. 116-260/H.R. 133 - Consolidated Appropriations Act of 2021 - Issues related to the fight against COVID-19 and coverage of medications indirectly related to the treatment of cancer patients during the pandemic as well as provisions designed to bolster the nation's biosimilars marketplace. H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders. Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards and coverage in the 340b program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 6074
Families First Coronavirus Response Act
2020 · fourth_quarter · Firm: RED+BLUE STRATEGIES
Most Favored Nation Prescription Drug Regulations and Executive Orders promulgated by the Administration and its impact on biosimilars. P.L. 116-260/H.R. 133 - Consolidated Appropriations Act of 2021 - Issues related to the fight against COVID-19 and coverage of medications indirectly related to the treatment of cancer patients during the pandemic as well as provisions designed to bolster the nation's biosimilars marketplace. H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders. Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards and coverage in the 340b program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 6201
Most Favored Nation Prescription Drug Regulations and Executive Orders promulgated by the Administration and its impact on biosimilars. P.L. 116-260/H.R. 133 - Consolidated Appropriations Act of 2021 - Issues related to the fight against COVID-19 and coverage of medications indirectly related to the treatment of cancer patients during the pandemic as well as provisions designed to bolster the nation's biosimilars marketplace. H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders. Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards and coverage in the 340b program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 748
Continuing Appropriations Act, 2021 and Other Extensions Act
2020 · fourth_quarter · Firm: RED+BLUE STRATEGIES
Most Favored Nation Prescription Drug Regulations and Executive Orders promulgated by the Administration and its impact on biosimilars. P.L. 116-260/H.R. 133 - Consolidated Appropriations Act of 2021 - Issues related to the fight against COVID-19 and coverage of medications indirectly related to the treatment of cancer patients during the pandemic as well as provisions designed to bolster the nation's biosimilars marketplace. H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders. Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards and coverage in the 340b program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 8319
Making emergency supplemental appropriations for the fiscal year ending September 30, 2021, and for other purposes.
2020 · fourth_quarter · Firm: RED+BLUE STRATEGIES
Most Favored Nation Prescription Drug Regulations and Executive Orders promulgated by the Administration and its impact on biosimilars. P.L. 116-260/H.R. 133 - Consolidated Appropriations Act of 2021 - Issues related to the fight against COVID-19 and coverage of medications indirectly related to the treatment of cancer patients during the pandemic as well as provisions designed to bolster the nation's biosimilars marketplace. H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders. Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards and coverage in the 340b program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 8406
Most Favored Nation Prescription Drug Regulations and Executive Orders promulgated by the Administration and its impact on biosimilars. P.L. 116-260/H.R. 133 - Consolidated Appropriations Act of 2021 - Issues related to the fight against COVID-19 and coverage of medications indirectly related to the treatment of cancer patients during the pandemic as well as provisions designed to bolster the nation's biosimilars marketplace. H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders. Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards and coverage in the 340b program.
Client expense: — · Firm income: $60,000
Matched citations: S. 1895
Source: Senate LDA